Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Abetimus sodium (LJP 394)
Abetimus · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| Abetimus sodium (LJP 394) | DRUG | - |
Inclusion Criteria * Diagnosed with SLE * Historical evidence of SLE renal disease * Elevated levels of dsDNA antibodies * Weight of 40 kg or greater Exclusion Criteria * Active SLE renal disease * Use of certain anti-inflammatory or cytotoxic therapies or therapeutic interventions during the mon...
Abetimus was developed for immunologic diseases, specifically lupus kidney disease, including systemic lupus erythematosus, lupus nephritis, and lupus glomerulonephritis. It is a small molecule therapeutic candidate studied in a Phase 3 clinical trial. It is not approved for any indication and remains investigational.
Abetimus is being developed by Innoviva, Inc., which trades under the ticker INVA. The company holds the development program for this small molecule candidate in immunology. No other developers are associated with the asset.
Abetimus is in Phase 3 development. One Phase 3 clinical trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any indication.
Abetimus has been studied in one completed Phase 3 trial, NCT00035308, titled Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease. The trial enrolled 330 participants across the United States, Austria, Canada, France, Germany, Italy, Mexico, Spain, Sweden, and the United Kingdom.
Yes, Abetimus is also known as Abetimus sodium, and it was formerly designated LJP 394. These names refer to the same small molecule drug candidate developed by Innoviva, Inc. for immunologic diseases.
The completed Phase 3 trial NCT00035308 was a randomized, double-blind study evaluating Abetimus sodium in lupus kidney disease. It enrolled 330 participants aged 12 years and older of all sexes. The trial was uncontrolled and did not use biomarker selection.